Humira Drug Market: Evaluating Market Share and Competitive Landscape in Biologic Therapeutics

The humira drug market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to introduction of biologics, biotechnology advancements, patient demand for effective treatments, physician adoption and prescribing patterns.

The humira drug market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to biosimilar market entry, healthcare policy changes, focus on cost-effectiveness, research and development investments, precision medicine and personalized treatments. Major trends in the forecast period include real-world evidence generation, expanded use in pediatric populations, shift towards self-administered medications, value-based pricing models, targeted therapies development.

Market Overview -
Humira drug, or adalimumab, refers to an injection prescribed to treat rheumatoid arthritis and other conditions. These drugs are used to reduce the pain and swelling caused by several types of arthritis.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=11934&type=smp

Growing Incidence Of Autoimmune Diseases Fuels Demand For Humira Drug
A rise in the incidence rate of autoimmune disease is expected to propel the growth of the humira drug market going forward. Autoimmune disease refers to a type of disease in which the body's immune system attacks and destroys healthy tissues and cells in the body. Humira drug is used to treat pain and inflammation caused by various autoimmune diseases, as a result, the rise in the incidence rate of autoimmune diseases increases the demand for humira drug. For instance, in July 2021, according to Cleveland Clinics, a US-based non-profit academic medical center, 1 in 15 people in the U.S. have an autoimmune disease. Further, one million people in the U.S. are suffering from lupus and 1.4 million have Crohn's disease or ulcerative colitis respectively. Therefore, the rise in the incidence rate of autoimmune disease will drive the HUMIRA drug market.

Competitive Landscape -
Major companies operating in the humira drug market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Celltrion Healthcare Co. Ltd., Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mochida Pharmaceutical Co. Ltd., Innovent Biologics Inc., Biocad Biopharmaceutical Company, Shanghai Henlius Biotech Inc., Glenmark Pharmaceuticals Ltd., Samsung Bioepis Co Ltd., Hetero Healthcare Ltd., Coherus BioSciences Inc., CinnaGen Co., Alvotech Holdings S.A, Reliance Life Sciences Private Limited, Momenta Pharmaceuticals Inc., Bio-Thera Solutions Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., BioXpress Therapeutics SA, Alteogen Inc., Prestige BioPharma Pte. Ltd.

Innovative Formulations Drive Advancements In Humira Drug Market
Product innovations are a key trend in the humira drug market. Major companies in the humira drug market are developing new biologics and biosimilars to sustain their position in the market. For instance, in April 2023, Sandoz, a Switzerland-based pharmaceutical company introduced Biosimilar Hyrimoz (adalimumab), a citrate-free high-concentration formulation (HCF) approved by the European Commission. The adalimumab citrate-free HCF (100 mg/mL) formulation provides a 50 % reduction in injection volume and decreases the number of injections required for patients opting for 80 mg/mL or higher dosing. This is applicable to various diseases such as rheumatic diseases, Crohn's disease, and others with enhanced familiar experience.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/humira-drug-global-market-report

Key Segments -

The humira drug market covered in this report is segmented -

1) By Type: Humira Syringe, Humira Pen
2) By Application: Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's Disease, Other Applications
3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.